A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Dose limiting toxicities (DLT) of OMP-59R5 in combination with nab-paclitaxel and gemcitabine
The maximum tolerated dose (MTD) will be determined in patients treated with OMP-59R5 in combination with nab-paclitaxel and gemcitabine
Subjects will be treated and observed for DLT through the end of the first cycle (28 days)
Yes
Eileen M O'Reilly, MD
Principal Investigator
Memorial Sloan-Kettering Cancer Center
United States: Food and Drug Administration
59R5-002
NCT01647828
October 2012
September 2016
Name | Location |
---|---|
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |
Greenville Hospital System | Greenville, South Carolina 29605 |
Rocky Mountain Cancer Centers | Thornton, Colorado 80260 |
Duke University Medical Center | Durham, North Carolina 27710 |
Bend Memorial Clinic | Bend, Oregon 97701 |
Sarah Cannon Research Institute | Nashville, Tennessee 37203 |
South Texas Accelerated Research Thereapeutics, LLC (START) | San Antonio, Texas 78229 |